199 related articles for article (PubMed ID: 19672917)
21. Structure-activity relationships of neuropeptide Y Y1 receptor antagonists related to BIBP 3226.
Aiglstorfer I; Hendrich I; Moser C; Bernhardt G; Dove S; Buschauer A
Bioorg Med Chem Lett; 2000 Jul; 10(14):1597-600. PubMed ID: 10915060
[TBL] [Abstract][Full Text] [Related]
22. N(ω)-Carbamoylation of the Argininamide Moiety: An Avenue to Insurmountable NPY Y1 Receptor Antagonists and a Radiolabeled Selective High-Affinity Molecular Tool ([(3)H]UR-MK299) with Extended Residence Time.
Keller M; Weiss S; Hutzler C; Kuhn KK; Mollereau C; Dukorn S; Schindler L; Bernhardt G; König B; Buschauer A
J Med Chem; 2015 Nov; 58(22):8834-49. PubMed ID: 26466164
[TBL] [Abstract][Full Text] [Related]
23. A rational approach for the development of reduced-size analogues of neuropeptide Y with high affinity to the Y1 receptor.
Rist B; Wieland HA; Willim KD; Beck-Sickinger AG
J Pept Sci; 1995; 1(5):341-8. PubMed ID: 9223013
[TBL] [Abstract][Full Text] [Related]
24. Establishment of robust functional assays for the characterization of neuropeptide Y (NPY) receptors: identification of 3-(5-benzoyl-thiazol-2-ylamino)-benzonitrile as selective NPY type 5 receptor antagonist.
Dautzenberg FM; Higelin J; Pflieger P; Neidhart W; Guba W
Neuropharmacology; 2005 Jun; 48(7):1043-55. PubMed ID: 15857631
[TBL] [Abstract][Full Text] [Related]
25. Internalization of neuropeptide Y Y1 and Y5 and of pancreatic polypeptide Y4 receptors is inhibited by lithium in preference to sodium and potassium ions.
Parker MS; Parker SL; Kane JK
Regul Pept; 2004 Apr; 118(1-2):67-74. PubMed ID: 14759559
[TBL] [Abstract][Full Text] [Related]
26. [³H]UR-MK136: a highly potent and selective radioligand for neuropeptide Y Y₁ receptors.
Keller M; Bernhardt G; Buschauer A
ChemMedChem; 2011 Sep; 6(9):1566-71. PubMed ID: 21732539
[No Abstract] [Full Text] [Related]
27. The bivalent ligand approach leads to highly potent and selective acylguanidine-type histamine H₂ receptor agonists.
Birnkammer T; Spickenreither A; Brunskole I; Lopuch M; Kagermeier N; Bernhardt G; Dove S; Seifert R; Elz S; Buschauer A
J Med Chem; 2012 Feb; 55(3):1147-60. PubMed ID: 22216892
[TBL] [Abstract][Full Text] [Related]
28. NPY Y1 antagonists: structure-activity relationships of arginine derivatives and hybrid compounds with arpromidine-like partial structures.
Aiglstorfer I; Uffrecht A; Gessele K; Moser C; Schuster A; Merz S; Malawska B; Bernhardt G; Dove S; Buschauer A
Regul Pept; 1998 Sep; 75-76():9-21. PubMed ID: 9802389
[TBL] [Abstract][Full Text] [Related]
29. Agonist induced receptor internalization of neuropeptide Y receptor subtypes depends on third intracellular loop and C-terminus.
Böhme I; Stichel J; Walther C; Mörl K; Beck-Sickinger AG
Cell Signal; 2008 Oct; 20(10):1740-9. PubMed ID: 18598760
[TBL] [Abstract][Full Text] [Related]
30. Towards understanding the free and receptor bound conformation of neuropeptide Y by fluorescence resonance energy transfer studies.
Haack M; Beck-Sickinger AG
Chem Biol Drug Des; 2009 Jun; 73(6):573-83. PubMed ID: 19635049
[TBL] [Abstract][Full Text] [Related]
31. Design and synthesis of specific probes for human 5-HT4 receptor dimerization studies.
Soulier JL; Russo O; Giner M; Rivail L; Berthouze M; Ongeri S; Maigret B; Fischmeister R; Lezoualc'h F; Sicsic S; Berque-Bestel I
J Med Chem; 2005 Oct; 48(20):6220-8. PubMed ID: 16190749
[TBL] [Abstract][Full Text] [Related]
32. BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist.
Doods H; Gaida W; Wieland HA; Dollinger H; Schnorrenberg G; Esser F; Engel W; Eberlein W; Rudolf K
Eur J Pharmacol; 1999 Nov; 384(2-3):R3-5. PubMed ID: 10611450
[TBL] [Abstract][Full Text] [Related]
33. Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains.
Nikolovska-Coleska Z; Meagher JL; Jiang S; Kawamoto SA; Gao W; Yi H; Qin D; Roller PP; Stuckey JA; Wang S
Anal Biochem; 2008 Mar; 374(1):87-98. PubMed ID: 18023397
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and evaluation of a novel cyclohexanamine class of neuropeptide Y Y1 receptor antagonists.
Cho K; Ando M; Kobayashi K; Miyazoe H; Tsujino T; Ito S; Suzuki T; Tanaka T; Tokita S; Sato N
Bioorg Med Chem Lett; 2009 Aug; 19(16):4781-5. PubMed ID: 19596193
[TBL] [Abstract][Full Text] [Related]
35. Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges.
Chini B; Manning M
Biochem Soc Trans; 2007 Aug; 35(Pt 4):737-41. PubMed ID: 17635137
[TBL] [Abstract][Full Text] [Related]
36. Assessment of a fully active class A G protein-coupled receptor isolated from in vitro folding.
Bosse M; Thomas L; Hassert R; Beck-Sickinger AG; Huster D; Schmidt P
Biochemistry; 2011 Nov; 50(45):9817-25. PubMed ID: 21999704
[TBL] [Abstract][Full Text] [Related]
37. Structural proof of a dimeric positive modulator bridging two identical AMPA receptor-binding sites.
Kaae BH; Harpsøe K; Kastrup JS; Sanz AC; Pickering DS; Metzler B; Clausen RP; Gajhede M; Sauerberg P; Liljefors T; Madsen U
Chem Biol; 2007 Nov; 14(11):1294-303. PubMed ID: 18022568
[TBL] [Abstract][Full Text] [Related]
38. The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists.
Lunniss GE; Barnes AA; Barton N; Biagetti M; Bianchi F; Blowers SM; Caberlotto L; Emmons A; Holmes IP; Montanari D; Norris R; Walters DJ; Watson SP
Bioorg Med Chem Lett; 2009 Aug; 19(15):4022-5. PubMed ID: 19581086
[TBL] [Abstract][Full Text] [Related]
39. Isomeric thiazole derivatives as ligands for the neuropeptide Y5 receptor.
Nettekoven M; Guba W; Neidhart W; Mattei P; Pflieger P; Roche O; Taylor S
Bioorg Med Chem Lett; 2005 Jul; 15(14):3446-9. PubMed ID: 15951170
[TBL] [Abstract][Full Text] [Related]
40. In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist.
Fang Q; Guo J; He F; Peng YL; Chang M; Wang R
Peptides; 2006 Sep; 27(9):2207-13. PubMed ID: 16762456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
